IntelGenx Technologies Corp. (IGXT)
USD 0.17
(0.0%)
USD 0.17
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 15.5 Million USD | 47.47% |
| 2022 | 10.51 Million USD | -8.34% |
| 2021 | 11.46 Million USD | 15.64% |
| 2020 | 9.91 Million USD | 12.86% |
| 2019 | 8.78 Million USD | 10.49% |
| 2018 | 7.95 Million USD | -0.14% |
| 2017 | 7.96 Million USD | 143.59% |
| 2016 | 3.26 Million USD | 88.96% |
| 2015 | 1.73 Million USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | -100.0% |
| 2008 | 796.85 Thousand USD | 53.58% |
| 2007 | 518.85 Thousand USD | 169.17% |
| 2006 | 192.76 Thousand USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 16.45 Million USD | 6.16% |
| 2023 Q2 | 14.18 Million USD | 0.28% |
| 2023 FY | 15.5 Million USD | 47.47% |
| 2023 Q4 | 15.5 Million USD | -0.22% |
| 2023 Q3 | 15.53 Million USD | 9.56% |
| 2023 Q1 | 14.14 Million USD | 34.53% |
| 2022 Q3 | 10.5 Million USD | -0.55% |
| 2022 Q4 | 10.51 Million USD | 0.03% |
| 2022 Q1 | 14.93 Million USD | 30.23% |
| 2022 Q2 | 10.56 Million USD | -29.24% |
| 2022 FY | 10.51 Million USD | -8.34% |
| 2021 Q2 | 11.26 Million USD | 0.61% |
| 2021 Q4 | 11.46 Million USD | -10.75% |
| 2021 FY | 11.46 Million USD | 15.64% |
| 2021 Q3 | 12.84 Million USD | 14.1% |
| 2021 Q1 | 11.19 Million USD | 12.87% |
| 2020 Q1 | 8.11 Million USD | -7.64% |
| 2020 Q2 | 8.1 Million USD | -0.09% |
| 2020 FY | 9.91 Million USD | 12.86% |
| 2020 Q3 | 8.27 Million USD | 2.04% |
| 2020 Q4 | 9.91 Million USD | 19.86% |
| 2019 FY | 8.78 Million USD | 10.49% |
| 2019 Q4 | 8.78 Million USD | 1.0% |
| 2019 Q3 | 8.69 Million USD | -1.96% |
| 2019 Q2 | 8.87 Million USD | 1.04% |
| 2019 Q1 | 8.78 Million USD | 10.44% |
| 2018 Q2 | 8.36 Million USD | 9.53% |
| 2018 Q3 | 8.42 Million USD | 0.69% |
| 2018 FY | 7.95 Million USD | -0.14% |
| 2018 Q4 | 7.95 Million USD | -5.6% |
| 2018 Q1 | 7.63 Million USD | -4.08% |
| 2017 Q1 | 3.12 Million USD | -4.56% |
| 2017 FY | 7.96 Million USD | 143.59% |
| 2017 Q4 | 7.96 Million USD | -2.01% |
| 2017 Q3 | 8.12 Million USD | 169.25% |
| 2017 Q2 | 3.01 Million USD | -3.27% |
| 2016 FY | 3.26 Million USD | 88.96% |
| 2016 Q4 | 3.26 Million USD | 5.42% |
| 2016 Q3 | 3.1 Million USD | -9.72% |
| 2016 Q2 | 3.43 Million USD | 50.46% |
| 2016 Q1 | 2.28 Million USD | 31.97% |
| 2015 Q1 | 395 Thousand USD | 0.0% |
| 2015 Q3 | 368 Thousand USD | -8.0% |
| 2015 FY | 1.73 Million USD | 0.0% |
| 2015 Q2 | 400 Thousand USD | 1.27% |
| 2015 Q4 | 1.73 Million USD | 370.11% |
| 2014 FY | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2009 Q3 | 93.7 Thousand USD | -91.68% |
| 2009 Q2 | 1.12 Million USD | 19.88% |
| 2009 Q4 | - USD | -100.0% |
| 2009 Q1 | 939.1 Thousand USD | 17.85% |
| 2009 FY | - USD | -100.0% |
| 2008 Q2 | 503.38 Thousand USD | -13.89% |
| 2008 Q4 | 796.85 Thousand USD | 15.14% |
| 2008 Q3 | 692.06 Thousand USD | 37.48% |
| 2008 Q1 | 584.55 Thousand USD | 12.66% |
| 2008 FY | 796.85 Thousand USD | 53.58% |
| 2007 Q2 | 530.91 Thousand USD | 181.65% |
| 2007 Q4 | 518.85 Thousand USD | 41.48% |
| 2007 Q1 | 188.5 Thousand USD | -2.21% |
| 2007 FY | 518.85 Thousand USD | 169.17% |
| 2007 Q3 | 366.73 Thousand USD | -30.92% |
| 2006 Q2 | 190.7 Thousand USD | 0.0% |
| 2006 Q4 | 192.76 Thousand USD | -7.1% |
| 2006 Q1 | - USD | 0.0% |
| 2006 FY | 192.76 Thousand USD | 0.0% |
| 2006 Q3 | 207.48 Thousand USD | 8.8% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| HST Global, Inc. | 98.31 Thousand USD | -15666.027% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -1949.844% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -6660.405% |
| CytoDyn Inc. | 30.07 Million USD | 48.461% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 73.037% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| MultiCell Technologies, Inc. | 202.58 USD | -7651691.885% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -227.351% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -164.023% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -10853.377% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -6095.889% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Alpha Cognition Inc. | 1.22 Million USD | -1170.186% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 65.977% |
| SQZ Biotechnologies Company | 27.47 Million USD | 43.573% |
| Resverlogix Corp. | 6.49 Million USD | -138.808% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -2360.176% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -428.974% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -546.488% |
| Mesoblast Limited | 118.7 Million USD | 86.941% |
| GB Sciences, Inc. | 1.75 Million USD | -781.086% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -1949.844% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 64.261% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | -19.266% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -5964.744% |
| ContraFect Corporation | 2.88 Million USD | -438.042% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -173.949% |
| BioStem Technologies, Inc. | 4.71 Million USD | -229.009% |
| LadRx Corporation | 33.6 Thousand USD | -46025.692% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -60170.617% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -211.078% |
| CSL Limited | 12.18 Billion USD | 99.873% |
| Biomind Labs Inc. | 735.54 Thousand USD | -2007.426% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -1053.705% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 47.926% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -12553.878% |
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 62.379% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -276.059% |
| GeneThera, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 53.171% |
| Adynxx, Inc. | - USD | -Infinity% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -1534.659% |
| Marizyme, Inc. | 18.71 Million USD | 17.184% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -1966.8% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -98.224% |
| Zenith Capital Corp. | 10.22 Thousand USD | -151499.022% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -566.436% |
| Halberd Corporation | 150 Thousand USD | -10234.0% |
| Genus plc | 233.1 Million USD | 93.35% |
| Pharming Group N.V. | 171.54 Million USD | 90.964% |
| MetaStat, Inc. | - USD | -Infinity% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -1645.482% |
| IMV Inc. | 28.88 Million USD | 46.333% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -3146.283% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Enzolytics Inc. | 996.33 Thousand USD | -1455.797% |
| argenx SE | 20 Million USD | 22.495% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -971.755% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Cell Source, Inc. | 9.25 Million USD | -67.503% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.49 Million USD | -937.029% |
| Q BioMed Inc. | 4.1 Million USD | -277.155% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -7247.316% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 23.746% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -1161.925% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -11340.95% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 77.084% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -412.228% |
| Rebus Holdings, Inc. | 310 Thousand USD | -4900.323% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| Skye Bioscience, Inc. | 4.61 Million USD | -235.864% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -4209.305% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -10327.57% |
| ONE Bio Corp. | 19.71 Million USD | 21.375% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -586.377% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -6132.309% |
| Agentix Corp. | 50 Thousand USD | -30902.0% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -119.163% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -472.267% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -7626.702% |
| Kadimastem Ltd | 891.22 Thousand USD | -1639.289% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -3757.419% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| NovAccess Global Inc. | 2.19 Million USD | -604.629% |
| Itoco Inc. | 228.37 Thousand USD | -6687.461% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -4305.608% |
| Mobile Lads Corp. | 484.28 Thousand USD | -3100.808% |
| Genscript Biotech Corporation | 417.73 Million USD | 96.289% |
| International Stem Cell Corporation | 4.17 Million USD | -271.015% |
| Bioxytran, Inc. | 1.92 Million USD | -705.247% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -24736.172% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -610.762% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | -86.4% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | -80.559% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -896.542% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -5683.955% |
| Neutra Corp. | 54.15 Thousand USD | -28522.867% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -747.049% |
| PureTech Health plc | 25.51 Million USD | 39.24% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -1166.188% |
| IXICO plc | 472.02 Thousand USD | -3183.95% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 75.104% |
| CSL Limited | 12.18 Billion USD | 99.873% |
| Cellectis S.A. | 92.77 Million USD | 83.292% |